SCHEMBL377204

SCHEMBL377204

CCCc1oc(-c2ccc(Cl)cc2)nc1CCC(=O)c1ccc(O)cc1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HSD17B3 P37058 8/20 0.43
MAPT P10636 2/20 0.42
TARBP2 Q15633 1/20 0.42
HSD17B10 Q99714 1/20 0.40
ESR1 P03372 1/20 0.40
ESR2 Q92731 1/20 0.40
PLTP P55058 2/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
PPARA Q07869 1/20 0.38
POLB P06746 2/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
GAA P10253 1/20 0.37
CTDSP1 Q9GZU7 1/20 0.37
TP53 P04637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL376528 0.83 PPARA (0.55) MAPTPPARAKDM4EALDH1A1
SCHEMBL377238 0.81 PPARA (0.53) MAPTTARBP2HSD17B10PPARAALDH1A1
SCHEMBL16398451 0.77 NOTUM (0.44) TARBP2HSD17B10PPARAPOLBKDM4E
SCHEMBL10653269 0.75 HSD17B10 (0.49) MAPTTARBP2HSD17B10PPARAPOLB
SCHEMBL11003486 0.70 KDM4E (0.47) TARBP2HSD17B10PPARAPOLBKDM4E
SCHEMBL18003020 0.70 POLB (0.44) TARBP2HSD17B10ESR1ESR2PPARA
SCHEMBL16399483 0.69 TARBP2 (0.56) MAPTTARBP2HSD17B10NPC1RAB9A
SCHEMBL376949 0.69 PPARG (0.51) MAPTHSD17B10ESR1ESR2NPC1
SCHEMBL11004559 0.68 HSD17B10 (0.57) MAPTTARBP2HSD17B10RAB9APPARA
SCHEMBL16398905 0.68 TARBP2 (0.45) TARBP2HSD17B10POLBKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1310494-B1 PPAR (delta) ACTIVATORS NIPPON CHEMIPHAR CO (JP) 2012-01-25 EP disclosed
US-6787552-B2 HYPERGLYCEMIA, HYPERLIPIDEMIA, OBESITY, SYNDROME X; OXAZOLE OR THIAZOLE OR IMIDAZOLE DERIVATIVES NIPPON CHEMIPHAR CO., LTD. (JP) 2004-09-07 US disclosed
US-20040097739-A1 Ppar delta activators NIPPON CHEMIPHAR CO., LTD. (JP) 2004-05-20 US disclosed
EP-1310494-A1 PPAR (delta) ACTIVATORS NIPPON CHEMIPHAR CO., LTD. (JP) 2003-05-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097739-A1 Ppar delta activators PPARD, PPARG, PPARA HSD17B3 165/4885MAPT 4859/4885TARBP2 3117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.